PROFLAVINE

/static/temp/default.svg

Search structure


Synonyms	Proflavine
Status
Molecule Category	Free-form
UNII	CY3RNB3K4T
EPA CompTox	DTXSID9043776


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WDVSHHCDHLJJJR-UHFFFAOYSA-N
Smiles	Nc1ccc2cc3ccc(N)cc3nc2c1
InChI	InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H11N3
Molecular Weight	209.25
AlogP	2.55
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	0.0
Polar Surface Area	64.93
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	16.0

Bioactivity

Mechanism of Action	Action	Reference
DNA disrupting agent	DISRUPTING AGENT	PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Transferase	-	-	-	-	90-95

Assay Description	Organism	Bioactivity	Reference
Compound was evaluated for cytotoxicity against A2780 cell lines.	Homo sapiens	470.0 nM
Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.	Homo sapiens	470.0 nM
Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs	Homo sapiens	470.0 nM
Inhibition of purified telomerase of Euplotes aediculatus at 50 uM	Euplotes aediculatus	52.0 %
Inhibition of telomerase after assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM	Tetrahymena thermophila	90.0 %
Inhibition of telomerase before assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM	Tetrahymena thermophila	90.0 %
Inhibition of human telomerase after assembly using recombinant hTR and hTERT at 50 uM	Homo sapiens	90.0 %
Inhibition of human telomerase before assembly using recombinant hTR and hTERT at 50 uM	Homo sapiens	95.0 %
Antiamastigote activity against Leishmania infantum	Leishmania infantum	120.0 nM
Phototoxicity in transformed CHO cells after 24 hrs of UV irradiation by WST1 assay	Cricetulus griseus	520.0 nM
Binding affinity to human pre-hsa-mir-155 miRNA assessed as inhibition of dicer-catalysed (33P)-labelled pre-miRNA processing at 1 mM after 1 hr by PAGE analysis	Homo sapiens	93.0 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	97.06 %
SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	360.0 nM
MERS 3CL-Pro protease inhibition percentage at 10 µM by FRET kind of response from peptide substrate	Middle East respiratory syndrome	9.0 %
Chymotrypsin inhibition percentage at 10 µM by FRET kind of response from peptide substrate	Homo sapiens	16.3 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.0 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.0 %

Related Entries

Cross References

Resources	Reference
ChEBI	8452
ChEMBL	CHEMBL55400
DrugBank	DB01123
DrugCentral	2277
FDA SRS	CY3RNB3K4T
Human Metabolome Database	HMDB0015255
KEGG	C11181
PDB	PRL
PharmGKB	PA164748742
PubChem	7099
SureChEMBL	SCHEMBL27386
ZINC	ZINC000003775644

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).